nodes	percent_of_prediction	percent_of_DWPC	metapath
Efavirenz—CYP2B6—Thiotepa—urinary bladder cancer	0.214	0.375	CbGbCtD
Efavirenz—CYP3A4—Thiotepa—urinary bladder cancer	0.0657	0.115	CbGbCtD
Efavirenz—CYP2B6—Cisplatin—urinary bladder cancer	0.059	0.104	CbGbCtD
Efavirenz—CYP1A2—Fluorouracil—urinary bladder cancer	0.0407	0.0715	CbGbCtD
Efavirenz—CYP2B6—Doxorubicin—urinary bladder cancer	0.0396	0.0694	CbGbCtD
Efavirenz—CYP2C9—Fluorouracil—urinary bladder cancer	0.0367	0.0644	CbGbCtD
Efavirenz—CYP1A2—Etoposide—urinary bladder cancer	0.034	0.0597	CbGbCtD
Efavirenz—CYP2C9—Cisplatin—urinary bladder cancer	0.0312	0.0547	CbGbCtD
Efavirenz—CYP2D6—Doxorubicin—urinary bladder cancer	0.0191	0.0335	CbGbCtD
Efavirenz—CYP3A4—Etoposide—urinary bladder cancer	0.0178	0.0313	CbGbCtD
Efavirenz—CYP3A4—Doxorubicin—urinary bladder cancer	0.0122	0.0213	CbGbCtD
Efavirenz—CYP2C19—urine—urinary bladder cancer	0.00333	0.189	CbGeAlD
Efavirenz—CYP1A2—urine—urinary bladder cancer	0.00272	0.154	CbGeAlD
Efavirenz—CYP2C9—urine—urinary bladder cancer	0.00258	0.146	CbGeAlD
Efavirenz—CYP3A4—urine—urinary bladder cancer	0.00197	0.112	CbGeAlD
Efavirenz—CYP2D6—urine—urinary bladder cancer	0.00194	0.11	CbGeAlD
Efavirenz—CYP1A2—renal system—urinary bladder cancer	0.000666	0.0378	CbGeAlD
Efavirenz—CYP2B6—renal system—urinary bladder cancer	0.000638	0.0362	CbGeAlD
Efavirenz—CYP2C19—vagina—urinary bladder cancer	0.000591	0.0335	CbGeAlD
Efavirenz—CYP2B6—female reproductive system—urinary bladder cancer	0.000511	0.029	CbGeAlD
Efavirenz—CYP2C9—female reproductive system—urinary bladder cancer	0.000506	0.0287	CbGeAlD
Efavirenz—CYP3A4—renal system—urinary bladder cancer	0.000482	0.0273	CbGeAlD
Efavirenz—CYP2D6—renal system—urinary bladder cancer	0.000474	0.0269	CbGeAlD
Efavirenz—CYP2B6—vagina—urinary bladder cancer	0.000462	0.0262	CbGeAlD
Efavirenz—CYP3A4—female reproductive system—urinary bladder cancer	0.000386	0.0219	CbGeAlD
Efavirenz—CYP2D6—female reproductive system—urinary bladder cancer	0.00038	0.0215	CbGeAlD
Efavirenz—CYP2C19—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000201	0.00206	CbGpPWpGaD
Efavirenz—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000187	0.00192	CbGpPWpGaD
Efavirenz—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000186	0.00191	CbGpPWpGaD
Efavirenz—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000185	0.0019	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000184	0.00189	CbGpPWpGaD
Efavirenz—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000183	0.00188	CbGpPWpGaD
Efavirenz—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000182	0.00187	CbGpPWpGaD
Efavirenz—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000179	0.000569	CcSEcCtD
Efavirenz—Renal failure—Doxorubicin—urinary bladder cancer	0.000179	0.000567	CcSEcCtD
Efavirenz—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000178	0.000566	CcSEcCtD
Efavirenz—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000178	0.000566	CcSEcCtD
Efavirenz—Urticaria—Etoposide—urinary bladder cancer	0.000178	0.000564	CcSEcCtD
Efavirenz—Jaundice—Doxorubicin—urinary bladder cancer	0.000177	0.000563	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000177	0.00182	CbGpPWpGaD
Efavirenz—Rhinitis—Epirubicin—urinary bladder cancer	0.000177	0.000561	CcSEcCtD
Efavirenz—Body temperature increased—Etoposide—urinary bladder cancer	0.000177	0.000561	CcSEcCtD
Efavirenz—Abdominal pain—Etoposide—urinary bladder cancer	0.000177	0.000561	CcSEcCtD
Efavirenz—Hepatitis—Epirubicin—urinary bladder cancer	0.000176	0.00056	CcSEcCtD
Efavirenz—Eye disorder—Methotrexate—urinary bladder cancer	0.000176	0.000559	CcSEcCtD
Efavirenz—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000176	0.000559	CcSEcCtD
Efavirenz—Tinnitus—Methotrexate—urinary bladder cancer	0.000176	0.000558	CcSEcCtD
Efavirenz—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000176	0.000557	CcSEcCtD
Efavirenz—Asthenia—Cisplatin—urinary bladder cancer	0.000175	0.000556	CcSEcCtD
Efavirenz—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000175	0.000555	CcSEcCtD
Efavirenz—Sweating—Doxorubicin—urinary bladder cancer	0.000174	0.000553	CcSEcCtD
Efavirenz—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000174	0.000553	CcSEcCtD
Efavirenz—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000174	0.000552	CcSEcCtD
Efavirenz—Haematuria—Doxorubicin—urinary bladder cancer	0.000173	0.00055	CcSEcCtD
Efavirenz—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000173	0.00055	CcSEcCtD
Efavirenz—Urethral disorder—Epirubicin—urinary bladder cancer	0.000173	0.000549	CcSEcCtD
Efavirenz—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000172	0.000546	CcSEcCtD
Efavirenz—Angiopathy—Methotrexate—urinary bladder cancer	0.000171	0.000543	CcSEcCtD
Efavirenz—Sinusitis—Doxorubicin—urinary bladder cancer	0.000171	0.000542	CcSEcCtD
Efavirenz—Immune system disorder—Methotrexate—urinary bladder cancer	0.00017	0.000541	CcSEcCtD
Efavirenz—Dizziness—Fluorouracil—urinary bladder cancer	0.00017	0.00054	CcSEcCtD
Efavirenz—Visual impairment—Epirubicin—urinary bladder cancer	0.00017	0.00054	CcSEcCtD
Efavirenz—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00017	0.000539	CcSEcCtD
Efavirenz—Diarrhoea—Cisplatin—urinary bladder cancer	0.000167	0.00053	CcSEcCtD
Efavirenz—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000167	0.00053	CcSEcCtD
Efavirenz—Alopecia—Methotrexate—urinary bladder cancer	0.000167	0.000529	CcSEcCtD
Efavirenz—Vomiting—Gemcitabine—urinary bladder cancer	0.000166	0.000529	CcSEcCtD
Efavirenz—Rash—Gemcitabine—urinary bladder cancer	0.000165	0.000524	CcSEcCtD
Efavirenz—Dermatitis—Gemcitabine—urinary bladder cancer	0.000165	0.000524	CcSEcCtD
Efavirenz—Eye disorder—Epirubicin—urinary bladder cancer	0.000165	0.000523	CcSEcCtD
Efavirenz—Hypersensitivity—Etoposide—urinary bladder cancer	0.000165	0.000523	CcSEcCtD
Efavirenz—Tinnitus—Epirubicin—urinary bladder cancer	0.000164	0.000522	CcSEcCtD
Efavirenz—Erythema—Methotrexate—urinary bladder cancer	0.000164	0.000521	CcSEcCtD
Efavirenz—Malnutrition—Methotrexate—urinary bladder cancer	0.000164	0.000521	CcSEcCtD
Efavirenz—Headache—Gemcitabine—urinary bladder cancer	0.000164	0.000521	CcSEcCtD
Efavirenz—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000164	0.00052	CcSEcCtD
Efavirenz—Flushing—Epirubicin—urinary bladder cancer	0.000164	0.00052	CcSEcCtD
Efavirenz—Vomiting—Fluorouracil—urinary bladder cancer	0.000164	0.00052	CcSEcCtD
Efavirenz—Rhinitis—Doxorubicin—urinary bladder cancer	0.000164	0.00052	CcSEcCtD
Efavirenz—Hepatitis—Doxorubicin—urinary bladder cancer	0.000163	0.000518	CcSEcCtD
Efavirenz—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	0.000163	0.00167	CbGpPWpGaD
Efavirenz—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000162	0.000516	CcSEcCtD
Efavirenz—Rash—Fluorouracil—urinary bladder cancer	0.000162	0.000515	CcSEcCtD
Efavirenz—Dermatitis—Fluorouracil—urinary bladder cancer	0.000162	0.000515	CcSEcCtD
Efavirenz—Headache—Fluorouracil—urinary bladder cancer	0.000161	0.000512	CcSEcCtD
Efavirenz—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000161	0.000512	CcSEcCtD
Efavirenz—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000161	0.00051	CcSEcCtD
Efavirenz—Dysgeusia—Methotrexate—urinary bladder cancer	0.000161	0.00051	CcSEcCtD
Efavirenz—Asthenia—Etoposide—urinary bladder cancer	0.00016	0.000509	CcSEcCtD
Efavirenz—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00016	0.000509	CcSEcCtD
Efavirenz—Angiopathy—Epirubicin—urinary bladder cancer	0.00016	0.000508	CcSEcCtD
Efavirenz—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00016	0.000508	CcSEcCtD
Efavirenz—Immune system disorder—Epirubicin—urinary bladder cancer	0.000159	0.000506	CcSEcCtD
Efavirenz—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000159	0.000505	CcSEcCtD
Efavirenz—Back pain—Methotrexate—urinary bladder cancer	0.000159	0.000504	CcSEcCtD
Efavirenz—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000159	0.00163	CbGpPWpGaD
Efavirenz—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000159	0.00163	CbGpPWpGaD
Efavirenz—Pruritus—Etoposide—urinary bladder cancer	0.000158	0.000502	CcSEcCtD
Efavirenz—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	0.000158	0.00162	CbGpPWpGaD
Efavirenz—Arrhythmia—Epirubicin—urinary bladder cancer	0.000158	0.0005	CcSEcCtD
Efavirenz—Visual impairment—Doxorubicin—urinary bladder cancer	0.000157	0.000499	CcSEcCtD
Efavirenz—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000157	0.00161	CbGpPWpGaD
Efavirenz—Alopecia—Epirubicin—urinary bladder cancer	0.000156	0.000495	CcSEcCtD
Efavirenz—Nausea—Gemcitabine—urinary bladder cancer	0.000156	0.000494	CcSEcCtD
Efavirenz—Vomiting—Cisplatin—urinary bladder cancer	0.000155	0.000493	CcSEcCtD
Efavirenz—Vision blurred—Methotrexate—urinary bladder cancer	0.000155	0.000491	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000154	0.00159	CbGpPWpGaD
Efavirenz—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000154	0.00049	CcSEcCtD
Efavirenz—Rash—Cisplatin—urinary bladder cancer	0.000154	0.000489	CcSEcCtD
Efavirenz—Dermatitis—Cisplatin—urinary bladder cancer	0.000154	0.000488	CcSEcCtD
Efavirenz—Erythema—Epirubicin—urinary bladder cancer	0.000154	0.000488	CcSEcCtD
Efavirenz—Malnutrition—Epirubicin—urinary bladder cancer	0.000154	0.000488	CcSEcCtD
Efavirenz—Diarrhoea—Etoposide—urinary bladder cancer	0.000153	0.000486	CcSEcCtD
Efavirenz—Nausea—Fluorouracil—urinary bladder cancer	0.000153	0.000485	CcSEcCtD
Efavirenz—Eye disorder—Doxorubicin—urinary bladder cancer	0.000153	0.000484	CcSEcCtD
Efavirenz—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000152	0.00157	CbGpPWpGaD
Efavirenz—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000152	0.000483	CcSEcCtD
Efavirenz—Tinnitus—Doxorubicin—urinary bladder cancer	0.000152	0.000483	CcSEcCtD
Efavirenz—Anaemia—Methotrexate—urinary bladder cancer	0.000152	0.000481	CcSEcCtD
Efavirenz—Flushing—Doxorubicin—urinary bladder cancer	0.000152	0.000481	CcSEcCtD
Efavirenz—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000152	0.000481	CcSEcCtD
Efavirenz—Flatulence—Epirubicin—urinary bladder cancer	0.000151	0.00048	CcSEcCtD
Efavirenz—Tension—Epirubicin—urinary bladder cancer	0.000151	0.000478	CcSEcCtD
Efavirenz—Dysgeusia—Epirubicin—urinary bladder cancer	0.00015	0.000477	CcSEcCtD
Efavirenz—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.00015	0.00154	CbGpPWpGaD
Efavirenz—Nervousness—Epirubicin—urinary bladder cancer	0.000149	0.000474	CcSEcCtD
Efavirenz—Back pain—Epirubicin—urinary bladder cancer	0.000149	0.000472	CcSEcCtD
Efavirenz—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000149	0.00153	CbGpPWpGaD
Efavirenz—Angiopathy—Doxorubicin—urinary bladder cancer	0.000148	0.00047	CcSEcCtD
Efavirenz—Malaise—Methotrexate—urinary bladder cancer	0.000148	0.00047	CcSEcCtD
Efavirenz—Dizziness—Etoposide—urinary bladder cancer	0.000148	0.000469	CcSEcCtD
Efavirenz—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000147	0.000468	CcSEcCtD
Efavirenz—Vertigo—Methotrexate—urinary bladder cancer	0.000147	0.000468	CcSEcCtD
Efavirenz—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000147	0.000467	CcSEcCtD
Efavirenz—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000146	0.0015	CbGpPWpGaD
Efavirenz—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000146	0.000463	CcSEcCtD
Efavirenz—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000145	0.00149	CbGpPWpGaD
Efavirenz—Nausea—Cisplatin—urinary bladder cancer	0.000145	0.00046	CcSEcCtD
Efavirenz—CYP2B6—Biological oxidations—GSTP1—urinary bladder cancer	0.000145	0.00149	CbGpPWpGaD
Efavirenz—Vision blurred—Epirubicin—urinary bladder cancer	0.000145	0.000459	CcSEcCtD
Efavirenz—Alopecia—Doxorubicin—urinary bladder cancer	0.000144	0.000458	CcSEcCtD
Efavirenz—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000144	0.00148	CbGpPWpGaD
Efavirenz—Cough—Methotrexate—urinary bladder cancer	0.000143	0.000455	CcSEcCtD
Efavirenz—CYP2B6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000143	0.00147	CbGpPWpGaD
Efavirenz—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000142	0.000452	CcSEcCtD
Efavirenz—Convulsion—Methotrexate—urinary bladder cancer	0.000142	0.000451	CcSEcCtD
Efavirenz—Vomiting—Etoposide—urinary bladder cancer	0.000142	0.000451	CcSEcCtD
Efavirenz—Erythema—Doxorubicin—urinary bladder cancer	0.000142	0.000451	CcSEcCtD
Efavirenz—Malnutrition—Doxorubicin—urinary bladder cancer	0.000142	0.000451	CcSEcCtD
Efavirenz—Anaemia—Epirubicin—urinary bladder cancer	0.000142	0.000451	CcSEcCtD
Efavirenz—Agitation—Epirubicin—urinary bladder cancer	0.000141	0.000448	CcSEcCtD
Efavirenz—Rash—Etoposide—urinary bladder cancer	0.000141	0.000448	CcSEcCtD
Efavirenz—Dermatitis—Etoposide—urinary bladder cancer	0.000141	0.000447	CcSEcCtD
Efavirenz—Headache—Etoposide—urinary bladder cancer	0.00014	0.000445	CcSEcCtD
Efavirenz—Flatulence—Doxorubicin—urinary bladder cancer	0.00014	0.000445	CcSEcCtD
Efavirenz—Arthralgia—Methotrexate—urinary bladder cancer	0.00014	0.000444	CcSEcCtD
Efavirenz—Chest pain—Methotrexate—urinary bladder cancer	0.00014	0.000444	CcSEcCtD
Efavirenz—Myalgia—Methotrexate—urinary bladder cancer	0.00014	0.000444	CcSEcCtD
Efavirenz—Tension—Doxorubicin—urinary bladder cancer	0.000139	0.000443	CcSEcCtD
Efavirenz—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000139	0.000442	CcSEcCtD
Efavirenz—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000139	0.00143	CbGpPWpGaD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000139	0.00044	CcSEcCtD
Efavirenz—Malaise—Epirubicin—urinary bladder cancer	0.000138	0.00044	CcSEcCtD
Efavirenz—Discomfort—Methotrexate—urinary bladder cancer	0.000138	0.000438	CcSEcCtD
Efavirenz—Nervousness—Doxorubicin—urinary bladder cancer	0.000138	0.000438	CcSEcCtD
Efavirenz—Vertigo—Epirubicin—urinary bladder cancer	0.000138	0.000438	CcSEcCtD
Efavirenz—Syncope—Epirubicin—urinary bladder cancer	0.000138	0.000437	CcSEcCtD
Efavirenz—Back pain—Doxorubicin—urinary bladder cancer	0.000137	0.000436	CcSEcCtD
Efavirenz—Palpitations—Epirubicin—urinary bladder cancer	0.000136	0.000431	CcSEcCtD
Efavirenz—Confusional state—Methotrexate—urinary bladder cancer	0.000135	0.000429	CcSEcCtD
Efavirenz—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000135	0.000428	CcSEcCtD
Efavirenz—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000134	0.00138	CbGpPWpGaD
Efavirenz—Cough—Epirubicin—urinary bladder cancer	0.000134	0.000425	CcSEcCtD
Efavirenz—Vision blurred—Doxorubicin—urinary bladder cancer	0.000134	0.000425	CcSEcCtD
Efavirenz—CYP2B6—Biological oxidations—GSTM1—urinary bladder cancer	0.000133	0.00137	CbGpPWpGaD
Efavirenz—Convulsion—Epirubicin—urinary bladder cancer	0.000133	0.000422	CcSEcCtD
Efavirenz—Nausea—Etoposide—urinary bladder cancer	0.000133	0.000422	CcSEcCtD
Efavirenz—Hypertension—Epirubicin—urinary bladder cancer	0.000133	0.000421	CcSEcCtD
Efavirenz—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000132	0.000419	CcSEcCtD
Efavirenz—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000131	0.000417	CcSEcCtD
Efavirenz—Anaemia—Doxorubicin—urinary bladder cancer	0.000131	0.000417	CcSEcCtD
Efavirenz—CYP2B6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000131	0.00135	CbGpPWpGaD
Efavirenz—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000131	0.000416	CcSEcCtD
Efavirenz—Arthralgia—Epirubicin—urinary bladder cancer	0.000131	0.000415	CcSEcCtD
Efavirenz—Myalgia—Epirubicin—urinary bladder cancer	0.000131	0.000415	CcSEcCtD
Efavirenz—Chest pain—Epirubicin—urinary bladder cancer	0.000131	0.000415	CcSEcCtD
Efavirenz—Agitation—Doxorubicin—urinary bladder cancer	0.000131	0.000415	CcSEcCtD
Efavirenz—Anxiety—Epirubicin—urinary bladder cancer	0.00013	0.000414	CcSEcCtD
Efavirenz—Skin disorder—Methotrexate—urinary bladder cancer	0.00013	0.000413	CcSEcCtD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00013	0.000412	CcSEcCtD
Efavirenz—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000129	0.000411	CcSEcCtD
Efavirenz—Discomfort—Epirubicin—urinary bladder cancer	0.000129	0.00041	CcSEcCtD
Efavirenz—Malaise—Doxorubicin—urinary bladder cancer	0.000128	0.000407	CcSEcCtD
Efavirenz—Dry mouth—Epirubicin—urinary bladder cancer	0.000128	0.000406	CcSEcCtD
Efavirenz—Vertigo—Doxorubicin—urinary bladder cancer	0.000128	0.000405	CcSEcCtD
Efavirenz—Anorexia—Methotrexate—urinary bladder cancer	0.000128	0.000405	CcSEcCtD
Efavirenz—Syncope—Doxorubicin—urinary bladder cancer	0.000127	0.000405	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000127	0.0013	CbGpPWpGaD
Efavirenz—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000127	0.0013	CbGpPWpGaD
Efavirenz—Confusional state—Epirubicin—urinary bladder cancer	0.000126	0.000401	CcSEcCtD
Efavirenz—Palpitations—Doxorubicin—urinary bladder cancer	0.000126	0.000399	CcSEcCtD
Efavirenz—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000125	0.000396	CcSEcCtD
Efavirenz—Cough—Doxorubicin—urinary bladder cancer	0.000124	0.000394	CcSEcCtD
Efavirenz—Shock—Epirubicin—urinary bladder cancer	0.000123	0.000391	CcSEcCtD
Efavirenz—Convulsion—Doxorubicin—urinary bladder cancer	0.000123	0.000391	CcSEcCtD
Efavirenz—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000123	0.00126	CbGpPWpGaD
Efavirenz—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000123	0.00039	CcSEcCtD
Efavirenz—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000123	0.00039	CcSEcCtD
Efavirenz—Hypertension—Doxorubicin—urinary bladder cancer	0.000123	0.000389	CcSEcCtD
Efavirenz—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000123	0.00126	CbGpPWpGaD
Efavirenz—Tachycardia—Epirubicin—urinary bladder cancer	0.000122	0.000388	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000122	0.000387	CcSEcCtD
Efavirenz—Skin disorder—Epirubicin—urinary bladder cancer	0.000122	0.000386	CcSEcCtD
Efavirenz—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000121	0.000385	CcSEcCtD
Efavirenz—Insomnia—Methotrexate—urinary bladder cancer	0.000121	0.000385	CcSEcCtD
Efavirenz—Myalgia—Doxorubicin—urinary bladder cancer	0.000121	0.000384	CcSEcCtD
Efavirenz—Chest pain—Doxorubicin—urinary bladder cancer	0.000121	0.000384	CcSEcCtD
Efavirenz—Arthralgia—Doxorubicin—urinary bladder cancer	0.000121	0.000384	CcSEcCtD
Efavirenz—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000121	0.00124	CbGpPWpGaD
Efavirenz—Anxiety—Doxorubicin—urinary bladder cancer	0.000121	0.000383	CcSEcCtD
Efavirenz—Paraesthesia—Methotrexate—urinary bladder cancer	0.00012	0.000382	CcSEcCtD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00012	0.000381	CcSEcCtD
Efavirenz—Discomfort—Doxorubicin—urinary bladder cancer	0.00012	0.000379	CcSEcCtD
Efavirenz—Anorexia—Epirubicin—urinary bladder cancer	0.000119	0.000379	CcSEcCtD
Efavirenz—Dyspnoea—Methotrexate—urinary bladder cancer	0.000119	0.000379	CcSEcCtD
Efavirenz—Somnolence—Methotrexate—urinary bladder cancer	0.000119	0.000378	CcSEcCtD
Efavirenz—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000119	0.00122	CbGpPWpGaD
Efavirenz—Dry mouth—Doxorubicin—urinary bladder cancer	0.000118	0.000376	CcSEcCtD
Efavirenz—Dyspepsia—Methotrexate—urinary bladder cancer	0.000118	0.000374	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000118	0.00121	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000118	0.00121	CbGpPWpGaD
Efavirenz—Confusional state—Doxorubicin—urinary bladder cancer	0.000117	0.000371	CcSEcCtD
Efavirenz—Decreased appetite—Methotrexate—urinary bladder cancer	0.000116	0.00037	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000116	0.000367	CcSEcCtD
Efavirenz—Fatigue—Methotrexate—urinary bladder cancer	0.000115	0.000367	CcSEcCtD
Efavirenz—Pain—Methotrexate—urinary bladder cancer	0.000115	0.000364	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000114	0.000363	CcSEcCtD
Efavirenz—Shock—Doxorubicin—urinary bladder cancer	0.000114	0.000362	CcSEcCtD
Efavirenz—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000114	0.000361	CcSEcCtD
Efavirenz—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000114	0.00036	CcSEcCtD
Efavirenz—Insomnia—Epirubicin—urinary bladder cancer	0.000113	0.00036	CcSEcCtD
Efavirenz—Tachycardia—Doxorubicin—urinary bladder cancer	0.000113	0.000359	CcSEcCtD
Efavirenz—Skin disorder—Doxorubicin—urinary bladder cancer	0.000113	0.000358	CcSEcCtD
Efavirenz—Paraesthesia—Epirubicin—urinary bladder cancer	0.000113	0.000357	CcSEcCtD
Efavirenz—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000112	0.000356	CcSEcCtD
Efavirenz—Dyspnoea—Epirubicin—urinary bladder cancer	0.000112	0.000355	CcSEcCtD
Efavirenz—Somnolence—Epirubicin—urinary bladder cancer	0.000111	0.000354	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000111	0.00114	CbGpPWpGaD
Efavirenz—Anorexia—Doxorubicin—urinary bladder cancer	0.000111	0.000351	CcSEcCtD
Efavirenz—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00011	0.00035	CcSEcCtD
Efavirenz—Dyspepsia—Epirubicin—urinary bladder cancer	0.00011	0.00035	CcSEcCtD
Efavirenz—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00011	0.000348	CcSEcCtD
Efavirenz—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	0.000109	0.00112	CbGpPWpGaD
Efavirenz—Decreased appetite—Epirubicin—urinary bladder cancer	0.000109	0.000346	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000108	0.000344	CcSEcCtD
Efavirenz—Fatigue—Epirubicin—urinary bladder cancer	0.000108	0.000343	CcSEcCtD
Efavirenz—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000108	0.00111	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000107	0.0011	CbGpPWpGaD
Efavirenz—Constipation—Epirubicin—urinary bladder cancer	0.000107	0.00034	CcSEcCtD
Efavirenz—Pain—Epirubicin—urinary bladder cancer	0.000107	0.00034	CcSEcCtD
Efavirenz—Urticaria—Methotrexate—urinary bladder cancer	0.000106	0.000338	CcSEcCtD
Efavirenz—Body temperature increased—Methotrexate—urinary bladder cancer	0.000106	0.000336	CcSEcCtD
Efavirenz—Abdominal pain—Methotrexate—urinary bladder cancer	0.000106	0.000336	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000106	0.000335	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000106	0.00108	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000106	0.00108	CbGpPWpGaD
Efavirenz—Insomnia—Doxorubicin—urinary bladder cancer	0.000105	0.000333	CcSEcCtD
Efavirenz—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000104	0.000331	CcSEcCtD
Efavirenz—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000103	0.000328	CcSEcCtD
Efavirenz—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000103	0.000328	CcSEcCtD
Efavirenz—Somnolence—Doxorubicin—urinary bladder cancer	0.000103	0.000327	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000103	0.00105	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000103	0.00105	CbGpPWpGaD
Efavirenz—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000102	0.000325	CcSEcCtD
Efavirenz—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000102	0.000324	CcSEcCtD
Efavirenz—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000101	0.00032	CcSEcCtD
Efavirenz—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000101	0.00103	CbGpPWpGaD
Efavirenz—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	0.000101	0.00103	CbGpPWpGaD
Efavirenz—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.0001	0.000318	CcSEcCtD
Efavirenz—Fatigue—Doxorubicin—urinary bladder cancer	0.0001	0.000317	CcSEcCtD
Efavirenz—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	9.98e-05	0.00103	CbGpPWpGaD
Efavirenz—Urticaria—Epirubicin—urinary bladder cancer	9.96e-05	0.000316	CcSEcCtD
Efavirenz—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.93e-05	0.00102	CbGpPWpGaD
Efavirenz—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	9.92e-05	0.00102	CbGpPWpGaD
Efavirenz—Pain—Doxorubicin—urinary bladder cancer	9.92e-05	0.000315	CcSEcCtD
Efavirenz—Constipation—Doxorubicin—urinary bladder cancer	9.92e-05	0.000315	CcSEcCtD
Efavirenz—Body temperature increased—Epirubicin—urinary bladder cancer	9.91e-05	0.000315	CcSEcCtD
Efavirenz—Abdominal pain—Epirubicin—urinary bladder cancer	9.91e-05	0.000315	CcSEcCtD
Efavirenz—Hypersensitivity—Methotrexate—urinary bladder cancer	9.87e-05	0.000313	CcSEcCtD
Efavirenz—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.85e-05	0.00101	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	9.79e-05	0.00101	CbGpPWpGaD
Efavirenz—Asthenia—Methotrexate—urinary bladder cancer	9.61e-05	0.000305	CcSEcCtD
Efavirenz—Feeling abnormal—Doxorubicin—urinary bladder cancer	9.56e-05	0.000303	CcSEcCtD
Efavirenz—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	9.5e-05	0.000976	CbGpPWpGaD
Efavirenz—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	9.48e-05	0.000301	CcSEcCtD
Efavirenz—Pruritus—Methotrexate—urinary bladder cancer	9.48e-05	0.000301	CcSEcCtD
Efavirenz—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	9.25e-05	0.00095	CbGpPWpGaD
Efavirenz—Hypersensitivity—Epirubicin—urinary bladder cancer	9.23e-05	0.000293	CcSEcCtD
Efavirenz—Urticaria—Doxorubicin—urinary bladder cancer	9.21e-05	0.000292	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	9.2e-05	0.000945	CbGpPWpGaD
Efavirenz—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	9.17e-05	0.000942	CbGpPWpGaD
Efavirenz—Body temperature increased—Doxorubicin—urinary bladder cancer	9.17e-05	0.000291	CcSEcCtD
Efavirenz—Abdominal pain—Doxorubicin—urinary bladder cancer	9.17e-05	0.000291	CcSEcCtD
Efavirenz—Diarrhoea—Methotrexate—urinary bladder cancer	9.16e-05	0.000291	CcSEcCtD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	9.16e-05	0.000941	CbGpPWpGaD
Efavirenz—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	9.13e-05	0.000937	CbGpPWpGaD
Efavirenz—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	9.05e-05	0.000929	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	9e-05	0.000924	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	9e-05	0.000924	CbGpPWpGaD
Efavirenz—Asthenia—Epirubicin—urinary bladder cancer	8.99e-05	0.000285	CcSEcCtD
Efavirenz—CYP2B6—Metabolism—GSTZ1—urinary bladder cancer	8.88e-05	0.000912	CbGpPWpGaD
Efavirenz—Pruritus—Epirubicin—urinary bladder cancer	8.87e-05	0.000282	CcSEcCtD
Efavirenz—Dizziness—Methotrexate—urinary bladder cancer	8.86e-05	0.000281	CcSEcCtD
Efavirenz—Diarrhoea—Epirubicin—urinary bladder cancer	8.58e-05	0.000272	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	8.57e-05	0.00088	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	8.57e-05	0.00088	CbGpPWpGaD
Efavirenz—Hypersensitivity—Doxorubicin—urinary bladder cancer	8.54e-05	0.000271	CcSEcCtD
Efavirenz—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	8.53e-05	0.000876	CbGpPWpGaD
Efavirenz—Vomiting—Methotrexate—urinary bladder cancer	8.52e-05	0.00027	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	8.5e-05	0.000873	CbGpPWpGaD
Efavirenz—Rash—Methotrexate—urinary bladder cancer	8.45e-05	0.000268	CcSEcCtD
Efavirenz—Dermatitis—Methotrexate—urinary bladder cancer	8.44e-05	0.000268	CcSEcCtD
Efavirenz—CYP2B6—Metabolism—NAT1—urinary bladder cancer	8.41e-05	0.000864	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—GSTO2—urinary bladder cancer	8.41e-05	0.000864	CbGpPWpGaD
Efavirenz—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.41e-05	0.000864	CbGpPWpGaD
Efavirenz—Headache—Methotrexate—urinary bladder cancer	8.39e-05	0.000266	CcSEcCtD
Efavirenz—Asthenia—Doxorubicin—urinary bladder cancer	8.32e-05	0.000264	CcSEcCtD
Efavirenz—Dizziness—Epirubicin—urinary bladder cancer	8.29e-05	0.000263	CcSEcCtD
Efavirenz—Pruritus—Doxorubicin—urinary bladder cancer	8.21e-05	0.00026	CcSEcCtD
Efavirenz—Vomiting—Epirubicin—urinary bladder cancer	7.97e-05	0.000253	CcSEcCtD
Efavirenz—Nausea—Methotrexate—urinary bladder cancer	7.96e-05	0.000253	CcSEcCtD
Efavirenz—Diarrhoea—Doxorubicin—urinary bladder cancer	7.94e-05	0.000252	CcSEcCtD
Efavirenz—Rash—Epirubicin—urinary bladder cancer	7.9e-05	0.000251	CcSEcCtD
Efavirenz—Dermatitis—Epirubicin—urinary bladder cancer	7.9e-05	0.000251	CcSEcCtD
Efavirenz—Headache—Epirubicin—urinary bladder cancer	7.85e-05	0.000249	CcSEcCtD
Efavirenz—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	7.84e-05	0.000805	CbGpPWpGaD
Efavirenz—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.73e-05	0.000794	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—UGT2B7—urinary bladder cancer	7.7e-05	0.00079	CbGpPWpGaD
Efavirenz—Dizziness—Doxorubicin—urinary bladder cancer	7.67e-05	0.000243	CcSEcCtD
Efavirenz—Nausea—Epirubicin—urinary bladder cancer	7.45e-05	0.000236	CcSEcCtD
Efavirenz—Vomiting—Doxorubicin—urinary bladder cancer	7.37e-05	0.000234	CcSEcCtD
Efavirenz—Rash—Doxorubicin—urinary bladder cancer	7.31e-05	0.000232	CcSEcCtD
Efavirenz—Dermatitis—Doxorubicin—urinary bladder cancer	7.31e-05	0.000232	CcSEcCtD
Efavirenz—Headache—Doxorubicin—urinary bladder cancer	7.27e-05	0.000231	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	7.23e-05	0.000742	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—CYP4B1—urinary bladder cancer	6.93e-05	0.000712	CbGpPWpGaD
Efavirenz—Nausea—Doxorubicin—urinary bladder cancer	6.89e-05	0.000219	CcSEcCtD
Efavirenz—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	6.71e-05	0.000689	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	6.58e-05	0.000676	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—SLC19A1—urinary bladder cancer	6.54e-05	0.000672	CbGpPWpGaD
Efavirenz—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.49e-05	0.000667	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—PRSS3—urinary bladder cancer	6.38e-05	0.000655	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	6.36e-05	0.000653	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—NAT1—urinary bladder cancer	6.36e-05	0.000653	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.25e-05	0.000642	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	6.17e-05	0.000634	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	6.12e-05	0.000628	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	6.05e-05	0.000621	CbGpPWpGaD
Efavirenz—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.97e-05	0.000613	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	5.85e-05	0.000601	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—NAT1—urinary bladder cancer	5.85e-05	0.000601	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	5.82e-05	0.000597	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	5.8e-05	0.000595	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—NAT1—urinary bladder cancer	5.8e-05	0.000595	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.7e-05	0.000586	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	5.35e-05	0.000549	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	5.3e-05	0.000545	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	5.24e-05	0.000538	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	5.23e-05	0.000537	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—TYMP—urinary bladder cancer	5.1e-05	0.000524	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	4.95e-05	0.000509	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—NAT1—urinary bladder cancer	4.95e-05	0.000509	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	4.95e-05	0.000508	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.87e-05	0.0005	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	4.82e-05	0.000495	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	4.82e-05	0.000495	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	4.77e-05	0.00049	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—NAT2—urinary bladder cancer	4.61e-05	0.000474	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	4.55e-05	0.000467	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	4.53e-05	0.000465	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	4.51e-05	0.000463	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	4.43e-05	0.000455	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	4.39e-05	0.000451	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	4.08e-05	0.000419	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.03e-05	0.000414	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—RRM2—urinary bladder cancer	3.98e-05	0.000409	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.86e-05	0.000397	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	3.85e-05	0.000396	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—TYMP—urinary bladder cancer	3.85e-05	0.000396	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.82e-05	0.000393	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.82e-05	0.000393	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	3.75e-05	0.000386	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.7e-05	0.00038	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	3.69e-05	0.000379	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—ENO2—urinary bladder cancer	3.69e-05	0.000379	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	3.58e-05	0.000367	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—TYMP—urinary bladder cancer	3.54e-05	0.000364	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.52e-05	0.000362	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—TYMP—urinary bladder cancer	3.51e-05	0.000361	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.5e-05	0.000359	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—NAT2—urinary bladder cancer	3.48e-05	0.000358	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.37e-05	0.000347	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—NAT2—urinary bladder cancer	3.2e-05	0.000329	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.18e-05	0.000326	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.15e-05	0.000323	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.01e-05	0.000309	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—RRM2—urinary bladder cancer	3.01e-05	0.000309	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—TYMP—urinary bladder cancer	3e-05	0.000308	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.97e-05	0.000305	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—NQO1—urinary bladder cancer	2.97e-05	0.000305	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.9e-05	0.000298	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.88e-05	0.000296	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—ENO2—urinary bladder cancer	2.79e-05	0.000286	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	2.79e-05	0.000286	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.77e-05	0.000284	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.77e-05	0.000284	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.74e-05	0.000282	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—NAT2—urinary bladder cancer	2.71e-05	0.000279	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	2.7e-05	0.000277	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.66e-05	0.000273	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.56e-05	0.000263	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.56e-05	0.000263	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.54e-05	0.000261	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.54e-05	0.000261	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.52e-05	0.000259	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.48e-05	0.000255	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	2.48e-05	0.000254	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.46e-05	0.000253	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.43e-05	0.000249	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—RRM2—urinary bladder cancer	2.34e-05	0.000241	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.32e-05	0.000238	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—TYMS—urinary bladder cancer	2.3e-05	0.000237	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	2.28e-05	0.000234	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	2.28e-05	0.000234	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.25e-05	0.000231	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—GPX1—urinary bladder cancer	2.18e-05	0.000224	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.18e-05	0.000224	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	2.17e-05	0.000223	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—ENO2—urinary bladder cancer	2.17e-05	0.000223	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.16e-05	0.000222	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	2.14e-05	0.00022	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	2.1e-05	0.000216	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.1e-05	0.000215	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.07e-05	0.000213	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.07e-05	0.000212	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.05e-05	0.00021	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	2.01e-05	0.000207	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.99e-05	0.000204	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.9e-05	0.000195	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.87e-05	0.000192	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.81e-05	0.000186	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.81e-05	0.000186	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.75e-05	0.00018	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.74e-05	0.000179	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.73e-05	0.000178	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.72e-05	0.000177	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.72e-05	0.000177	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.72e-05	0.000177	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.71e-05	0.000175	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.7e-05	0.000174	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.67e-05	0.000172	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.67e-05	0.000172	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.65e-05	0.00017	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.65e-05	0.000169	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.63e-05	0.000168	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.62e-05	0.000167	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.62e-05	0.000166	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.6e-05	0.000164	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.59e-05	0.000163	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.58e-05	0.000163	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.58e-05	0.000163	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.57e-05	0.000161	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.57e-05	0.000161	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.57e-05	0.000161	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.52e-05	0.000156	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.52e-05	0.000156	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.5e-05	0.000154	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.49e-05	0.000153	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.48e-05	0.000152	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.48e-05	0.000152	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.46e-05	0.00015	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.41e-05	0.000145	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.4e-05	0.000144	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.39e-05	0.000142	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.36e-05	0.000139	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.35e-05	0.000139	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.34e-05	0.000138	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.34e-05	0.000138	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.28e-05	0.000132	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	1.28e-05	0.000132	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.26e-05	0.000129	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.23e-05	0.000127	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.18e-05	0.000122	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.18e-05	0.000122	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.13e-05	0.000116	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.13e-05	0.000116	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.12e-05	0.000115	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—PTEN—urinary bladder cancer	1.12e-05	0.000115	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.09e-05	0.000112	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.08e-05	0.000111	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—EP300—urinary bladder cancer	1.07e-05	0.00011	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.05e-05	0.000108	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.03e-05	0.000106	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.03e-05	0.000106	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—GPX1—urinary bladder cancer	9.91e-06	0.000102	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	9.73e-06	9.99e-05	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	9.7e-06	9.96e-05	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—PPARG—urinary bladder cancer	9.61e-06	9.87e-05	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	9.23e-06	9.48e-05	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	9.15e-06	9.39e-05	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	8.92e-06	9.16e-05	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	8.85e-06	9.08e-05	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—PTEN—urinary bladder cancer	8.46e-06	8.69e-05	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—EP300—urinary bladder cancer	8.07e-06	8.29e-05	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—PTEN—urinary bladder cancer	7.78e-06	7.99e-05	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—PTEN—urinary bladder cancer	7.71e-06	7.92e-05	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	7.56e-06	7.76e-05	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—EP300—urinary bladder cancer	7.42e-06	7.62e-05	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—PPARG—urinary bladder cancer	7.42e-06	7.62e-05	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—EP300—urinary bladder cancer	7.36e-06	7.56e-05	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	7.12e-06	7.32e-05	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—PTEN—urinary bladder cancer	6.59e-06	6.77e-05	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—EP300—urinary bladder cancer	6.29e-06	6.46e-05	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.83e-06	5.99e-05	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.09e-06	5.23e-05	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.85e-06	4.98e-05	CbGpPWpGaD
